🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Nutriband Inc. NTRB PHARMA

Healthcare · Biotechnology · United States
https://www.nutriband.com
Company Profile ↓
$6.10
-8.41% 1Y
Mkt Cap$74.15M
P/E-12.45
P/B18.56
52W High$8.50
52W Low$2.81
Book Value$0.44
EPS (TTM)$-0.49

Company Overview

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 42.3% CAGR over the past five years.

Recent Developments

  • Jan 2026 Revenue of $2.04M (-4.8% YoY); net profit $-8.23M.
  • Trailing 12 Months Year-on-year growth — revenue -29.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 42.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:42.30%
1 Year:-29.70%

Stock Price Performance

1 Year:-8.41%
6 Months:+43.53%
3 Months:+72.80%
1 Month:+96.14%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 58% of range
$2.81 $8.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)80.22 · Overbought
Price Performance
1M+96.14%
3M+72.80%
6M+43.53%
1Y-8.41%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 42.3% over 5 years.

CONS

  • Trading 28.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 80 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-12.45
Industry PE
24.83
Forward P/E
-26.52
PEG Ratio
-
Book Value
$0.44
Price to Book
18.56
P/S
61.09
EV/EBITDA
-13.01
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
42.30%
Profit 5Y
-
Revenue (YoY)
-29.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-122.98%
ROE
-100.75%
ROA
-53.48%
Profit Margin
0.00%
Op Margin
-
Gross Margin
33.14%
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$-0.49

Balance Sheet & Liquidity

Debt/Equity
4.12
Quick Ratio
3.80
Current Ratio
4.21
Debt
$219.72K
Total Assets
$6.89M
Current Assets
$4.38M
Working Capital
$4.20M

Ownership

Promoter Holding
59.09%
Chg in Prom Hold
2.27%
FII / Inst Holding
2.90%
Chg in FII Hold
-0.19%

Financial Snapshot

Enterprise Value
$74.15M
Total Revenue (TTM)
$1.62M
EBITDA
$-6.90M
Free Cash Flow
$-1.41M
Operating Cash Flow
$-3.63M
Shares Outstanding
12.16M
Gross Margin
33.14%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NTRB Nutriband Inc. PHARMA 6.10 -12.45 $74.15M 0.00% -122.98% -100.75% 42.30% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Apr 2016Jul 2016Oct 2016Apr 2017Jul 2017Oct 2017Apr 2018Jul 2018Oct 2018Apr 2019Jul 2019Oct 2019Apr 2020Jul 2020Oct 2020Apr 2021Jul 2021Oct 2021Apr 2022Jul 2022Oct 2022Apr 2023Jul 2023Oct 2023Apr 2024Jul 2024Oct 2024Jan 2025Apr 2025Jul 2025Oct 2025Jan 2026Apr 2026
Revenue --------162.81K193.59K74.91K82.57K119.36K84.45K391.80K433.49K213.74K283.04K477.92K456.15K618.00K476.93K655.93K427.84K408.53K442.83K645.80K-667.43K622.45K346.06K400.71K433.40K
Cost of Revenue ----------------------------415.45K465.57K277.55K311.77K236.60K
Gross Profit ---------------237.88K-71675.34K200.49K151.80K268.19K-299.67K159.72K164.79K101.56K191.03K-251.98K156.88K68.50K88.94K196.80K
Operating Expenses ----------------------------1.67M2.16M3.95M1.11M1.45M
Operating Income -52.08K-35.62K-29.98K-35.62K-92.96K-107.73K-448.10K-1.88M-488.62K-573.16K-449.61K-330.57K-147.49K-225.82K-40.95K-314.06K-482.24K-1.54M-685.88K-1.03M-1.07M-1.02M-824.19K-1.72M-1.89M-1.41M-1.43M--1.41M-2.00M-3.88M-1.02M-1.25M
EBITDA -----------------------------1.33M-1.94M-3.82M-926.85K-1.20M
Interest Expense ----------------------------5.88K5.77K5.55K5.33K5.01K
Pretax Income -----------------------------1.39M-2.00M-3.87M-968.06K-1.24M
Tax Provision ----------------------------00000
Net Income -52.08K-35.62K-29.98K-35.62K-92.96K-107.73K-448.10K-1.88M-488.62K-573.35K-450.56K-753.27K-412.19K-225.87K-42.57K-315.96K-519.92K-1.57M-689.99K-1.04M-1.08M-1.02M-829.17K-1.76M-1.90M-1.71M-1.36M--1.39M-2.00M-3.87M-968.06K-1.24M
Diluted EPS -----------------0.07-0.23-0.08-0.12-0.14-0.13-0.11-0.22-0.21-0.15-0.12--0.12-2.12-0.32--0.10
R&D Expense -----------------161.00K117.81K277.87K290.72K400.43K445.12K551.50K974.53K773.98K880.77K-683.43K562.55K457.11K-247.26K

Profit & Loss (Annual)

Figures in USD.

Metric Jan 2017Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026
Revenue --245.28K370.65K943.70K-2.08M2.09M2.14M2.04M
Cost of Revenue ------1.33M1.22M1.40M1.47M
Gross Profit ----316.23K-750.41K862.11K743.32K566.31K
Operating Expenses ------4.90M5.73M7.43M8.88M
Operating Income -151.26K-2.67M-3.33M-1.97M-2.60M--4.15M-4.87M-6.69M-8.32M
EBITDA -------4.15M-5.12M-10.18M-8.01M
Interest Expense ------8.29K75.81K21.41K22.54K
Pretax Income -------4.48M-5.49M-10.48M-8.23M
Tax Provision ------0000
Net Income -151.26K-2.67M-3.33M-2.72M-2.93M--4.48M-5.49M-10.48M-8.23M
Diluted EPS -------0.53-0.69-0.99-2.58
R&D Expense -----411.38K982.23K1.96M3.12M1.89M

Balance Sheet (Annual)

Figures in USD.

Metric Jan 2016Oct 2016Jan 2017Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026
Total Assets 330-37.73K164.90K2.81M2.20M9.93M-9.46M7.52M7.47M7.55M
Current Assets --------2.69M1.02M4.79M4.99M
Cash & Equivalents 1006.23K27.12K-474.65K10.18K151.99K-1.99M492.94K4.31M4.57M
Inventory --------229.34K168.60K212.04K117.99K
Receivables --------113.05K148.65K73.85K118.40K
Total Liabilities 11.80K-14.62K--2.02M2.82M-883.39K1.08M1.04M868.45K
Current Liabilities 11.11K-14.62K43.39K403.01K2.02M2.57M-748.61K999.09K982.85K784.28K
Long Term Debt 686-1.58K1.82K----100.50K79.83K58.20K35.86K
Total Debt --------185.81K241.28K186.35K245.49K
Total Equity -11.47K-23.11K121.51K2.40M175.43K7.11M-8.57M6.44M6.43M6.68M
Shares Outstanding --------7.84M8.87M11.11M12.17M

Cash Flows (Annual)

Figures in USD.

Metric Jan 2017Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026
Operating Cash Flow -147.92K-92.86K-1.11M-894.47K-297.06K--2.99M-3.53M-4.63M-5.13M
Investing Cash Flow ---404.16K-66.99K--79.30K-51.76K-92.04K-5.32K
Financing Cash Flow 174.90K65.76K1.98M430.25K371.87K-160.07K2.09M8.54M5.40M
Capital Expenditure ---4.16K----79.30K-51.76K-92.04K-5.32K
Free Cash Flow ---1.11M----3.07M-3.58M-4.72M-5.14M
Net Change in Cash -------2.91M-1.49M3.82M263.14K

Ratios (Annual)

Figures in %.

Metric Jan 2017Jan 2018Jan 2019Jan 2020Jan 2021Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026
Gross Margin % ----33.5%-36.1%41.3%34.7%27.8%
Operating Margin % ---1,358.1%-531.4%-275.1%--199.5%-233.6%-312.7%-408.4%
Net Margin % ---1,358.1%-734.3%-310.8%--215.6%-263.0%-489.9%-404.1%
ROE % -654.6%-2,199.0%-138.5%-1,551.4%-41.2%--52.3%-85.2%-163.1%-123.2%
ROCE % -654.6%-2,199.0%-138.5%-1,122.6%-35.3%--47.6%-74.7%-103.1%-123.0%

Shareholding Pattern

Insiders
59.09%
Institutions
2.90%
Public Float
7.09%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 2.75% 174.93K $1.42M
2 Geode Capital Management, LLC 0.98% 62.49K $508.08K
3 Vanguard Fiduciary Trust Co 0.40% 25.11K $204.15K
4 State Street Corporation 0.39% 24.97K $202.97K
5 Citadel Advisors Llc 0.30% 19.00K $154.44K
6 Haven Private, LLC 0.18% 11.37K $92.41K
7 Northern Trust Corporation 0.18% 11.57K $94.06K
8 Blackrock Inc. 0.17% 10.66K $86.68K
9 Osaic Holdings Inc. 0.06% 3.68K $29.95K
10 Vanguard Global Advisers, LLC 0.04% 2.70K $21.95K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NTRB

Google News ue, 08 Sep 2026

Nutriband’s proposed fentanyl patch brand enters a 30-day opposition period - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNbU5NR0tMeC1LQy16bm82NGhWUVYyT3BIZ21HdUxmWjRyWDZzVTNfNWtZMllfTEFxUTJKX1dodXRfWS12SWdzSWgtVGZYbmR5MnV2ZVRBSVlIT1FteFJRREYwUkJFZHNheS01eEVWWGNhY3l0TTc5M3RkOVZidno0eTB2T052NkRKTkMwWn…

Google News Sat, 05 Sep 2026

Nutriband Stock Price Forecast. Should You Buy NTRB? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFAzUVJLUFdmUW9ES0YwbjRkRFZveE1Gci16ZDJTUjJXUkZ5V2dtMHZYeklIVzRuSUZXLTN3OF9uSWI5dXNLWnlMMg?oc=5" target="_blank">Nutriband Stock Price Forecast. Should You Buy NTRB?</a>&nbsp;&nbsp;<…

Google News ue, 08 Sep 2026

(NTRB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPSDhlZnJUdmVEVDRKVEpFREl6UzJ1bUdXMlZmYWZvWXVoODlYb0tjWWJpMkJqX1VUWS1BalhjeElPVU1Zcm1YbTZwRkhaTEY5c2g1RU5CbThBR3V0LTBiaVRJUWlQRVMwSTBaR3pnMThWUXVWeHJnekh0alhaMloxUEZKckxXWTd3X09TbX…

Google News ue, 08 Sep 2026

NTRB Looks 112.1% Overvalued on GF Value™ - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOSlFLWVBfUENhYzRPQ2dKd3VEVXUxekcyS3BNb3FhU0t5MnVKQmQ3ams5c2xvVXh6b294Qjd0OXBDYjRsQjRXeUM2ckZ0eGxKZEpScVZ3SVBjSDVFdzQxOExhYVlNVi00Y2VQbjZFcjNIXzd4ZWpXV3RpNExWcmtsNmE0VQ?oc=5" targe…

Google News hu, 29 Jan 2026

The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPd0FZQ29mcGJlbHBrdzNWSnZlTU5hNkRyTmZLYy1sRmFTQmlxQ2FGS3FMYzJ1NGZESWl4MTRiSFUyWk1sb2pxTTlIdzhOcmtmRXpyZF82ZGMwUFVtbmpPeGZaY1h4OHRxcDZnUkhDTXI1VThBMk5fMHV5RTkycXFLN2NSNUw?oc=5" targ…

Google News Fri, 04 Sep 2026

Nutriband Inc (NTRB) EPS 2026: $2.58 loss per share - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE84YXd5VVJGUzhBMjltN3pRaTFCOTlMemFndDFXclFKZGtSVWZkdjY3TzdCT1k0bHRqWmdwVUF4VXQwZkkyX011elVCdjFLQjJicGlwWk9DWG5yT1U?oc=5" target="_blank">Nutriband Inc (NTRB) EPS 2026: $2.58 loss pe…

NTRB — Frequently Asked Questions

What is the current share price of Nutriband Inc. (NTRB)?

As of 2026-09-19 21:16 PDT, Nutriband Inc. (NTRB) trades at $6.10 on NasdaqCM. Its 52-week range is $2.81 to $8.50.

What is the market capitalisation of NTRB?

Nutriband Inc. (NTRB) has a market capitalisation of $74.15M on NasdaqCM.

What is the P/E ratio of NTRB?

NTRB trades at a trailing price-to-earnings (P/E) ratio of -12.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 18.56.

What is the return on equity (ROE) of NTRB?

NTRB has a return on equity (ROE) of -100.75%. Its return on capital employed (ROCE) is -122.98%.

Is NTRB a good stock to buy?

This page provides a data-driven analysis of Nutriband Inc. (NTRB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space